Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma
暂无分享,去创建一个
Chung-Che Chang | Brent Logan | Andre Kajdacsy-Balla | S. Perkins | C. Chang | A. Kajdacsy-Balla | D. Vesole | B. Logan | R. Cleveland | Sherrie L Perkins | David H Vesole | Sara McClintock | Ronald P Cleveland | Trent Trzpuc | S. McClintock | Trent D Trzpuc
[1] D. Carey,et al. Syndecans: multifunctional cell-surface co-receptors. , 1997, The Biochemical journal.
[2] R Tibshirani,et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.
[3] S. Swerdlow,et al. Immunophenotypic and Genotypic Markers of Follicular Center Cell Neoplasia in Diffuse Large B-Cell Lymphomas , 2000, Modern Pathology.
[4] S. Kroft,et al. Assessment of CD10 in the diagnosis of small B-cell lymphomas: a multiparameter flow cytometric study. , 2002, American journal of clinical pathology.
[5] L. Kjellén,et al. Proteoglycans: structures and interactions. , 1991, Annual review of biochemistry.
[6] G. Gaidano,et al. MUM1: a step ahead toward the understanding of lymphoma histogenesis , 2000, Leukemia.
[7] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[8] S. Barrans,et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.
[9] K. Ohshima,et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B‐cell lymphomas , 1999, Pathology international.
[10] J Hermans,et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.
[11] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[12] Emili Montserrat,et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.
[13] I. Hanamura,et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies , 2000, Leukemia.
[14] K. Ohshima,et al. CD10 and Bcl10 expression in diffuse large B‐cell lymphoma: CD10 is a marker of improved prognosis , 2001, Histopathology.
[15] L. Larocca,et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. , 1998, Blood.
[16] C. Ross,et al. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. , 2001, American journal of clinical pathology.
[17] L. Larocca,et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. , 2001, Blood.
[18] G. Brittinger,et al. Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group , 1984, Hematological oncology.
[19] Z. Kaleem,et al. Critical analysis and diagnostic usefulness of limited immunophenotyping of B-cell non-Hodgkin lymphomas by flow cytometry. , 2001, American journal of clinical pathology.
[20] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[21] S. Perkins,et al. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. , 2000, American journal of clinical pathology.
[22] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[23] B. Barlogie,et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. , 1998, Blood.
[24] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[25] R. Sanderson,et al. B lymphocytes express and lose syndecan at specific stages of differentiation. , 1989, Cell regulation.
[26] K. Molberg,et al. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. , 2001, American journal of clinical pathology.
[27] Paul J. Kurtin,et al. Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. , 1999, American journal of clinical pathology.
[28] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[29] L. Berczi,et al. Syndecan‐1 (CD138) expression in human non‐Hodgkin lymphomas , 1999, British journal of haematology.
[30] CD10 expression and survival. , 2002, American journal of clinical pathology.
[31] S. Franceschi,et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. , 1998, Blood.
[32] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[33] V. Zagonel,et al. Follicular lymphoma of compartmentalized small cleaved center cells and mantle zone lymphocytes. Evidence for a common derivation. , 1992, American journal of clinical pathology.
[34] Yasodha Natkunam,et al. Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry , 2001, Modern Pathology.
[35] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[36] J. D. Capra,et al. Analysis of somatic mutation in five B cell subsets of human tonsil , 1994, The Journal of experimental medicine.
[37] F. Mitelman,et al. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. , 2002, International journal of oncology.
[38] M. Neuberger,et al. Somatic hypermutation of immunoglobulin genes. , 1996, Annual review of immunology.
[39] S. Perkins,et al. Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. , 2001, American journal of clinical pathology.